Characterization of Three CYP2C19 Gene Variants by MassARRAY and Point of Care Techniques: Experience from a Czech Centre.
Martin PetrekLenka KocourkovaVeronika ZizkovaZdenek NosekMilos TaborskyJana PetrkovaPublished in: Archivum immunologiae et therapiae experimentalis (2017)
Distribution of cytochrome P450 2C19 enzyme gene (CYP2C19) variants affecting metabolism of clopidogrel was determined in 526 Czech patients after percutaneous coronary intervention using MassARRAY genotyping and compared to distribution in other populations of European descent. Fifty-three (10%) patients underwent parallel determination of CYP2C19 genotypes from buccal swabs by a point of care technique with 100% concordance to the main genotyping platform. Observed CYP2C19 genotypes were related to clopidogrel metabolism phenotypes and discussed in population context. Hereby, presented methodologies provide accurate CYP2C19 genotyping results in a relatively short time of one up to 12 h and may, therefore, find the relevant place in the field of genotype-guided antiplatelet therapy.
Keyphrases
- percutaneous coronary intervention
- antiplatelet therapy
- acute coronary syndrome
- end stage renal disease
- genome wide
- copy number
- ejection fraction
- newly diagnosed
- high throughput
- chronic kidney disease
- acute myocardial infarction
- peritoneal dialysis
- st segment elevation myocardial infarction
- prognostic factors
- st elevation myocardial infarction
- high resolution
- dna methylation
- patient reported outcomes
- coronary artery bypass grafting
- left ventricular
- solid phase extraction
- coronary artery bypass